The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Apr 2016 07:00

RNS Number : 2811U
Scancell Holdings Plc
06 April 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Calculus Capital Limited

4. Full name of shareholder(s)  (if different from 3.):iv

Reyker Nominees/Investec Wealth and Investment

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

5 April 2016

6. Date on which issuer notified:

5 April 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

16%, 17%, 18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ISIN: GB00B63D3314

35,085,706

35,085,706

49,203,353

49,203,353

18.8%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

49,203,353

18.8%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Calculus Capital Limited

15. Contact telephone number:

0207 493 4940

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFLTSEIEIIR
Date   Source Headline
29th Jun 20164:35 pmRNSPrice Monitoring Extension
17th Jun 20167:00 amRNSSCIB1 Drug Product Supply
2nd Jun 20167:00 amRNSDevelopment of ImmunoBody® Vaccine
18th May 20167:00 amRNSOpens US Headquarters in San Diego
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
11th Apr 20164:11 pmRNSHolding(s) in Company
6th Apr 20167:00 amRNSHolding(s) in Company
4th Apr 201610:17 amRNSResult of the open offer
1st Apr 20167:00 amRNSResult of open offer
23rd Mar 20167:00 amRNSWorld Cancer Vaccine Congress
11th Mar 20167:00 amRNSPosting of Circular
11th Mar 20167:00 amRNSStrategic collaboration with Karolinska Institutet
9th Mar 20162:07 pmRNSPlacing and Open Offer Close
9th Mar 20167:00 amRNSProposed Placing and Open Offer
23rd Feb 20167:00 amRNSPresenting at the Biotech Capital Conference
27th Jan 20169:00 amRNSAmendment to Options
27th Jan 20167:00 amRNSHalf Yearly Report
11th Jan 20167:00 amRNSSCIB1 Early Immune Effect Observed by ImmunTraCkeR
7th Jan 20167:00 amRNSDirectorate Change
5th Jan 20167:00 amRNSKey Moditope paper published in Cancer Research
18th Dec 20157:00 amRNSUS Phase II combination study with SCIB1
20th Oct 20151:05 pmRNSResults of AGM
20th Oct 20157:00 amRNSAGM Business Update
14th Oct 20157:00 amRNSDirectorate Change
6th Oct 20157:00 amRNSSix scientific presentations at PIVAC Conference
18th Sep 20157:00 amRNSFinal Results for the year ended 30 April 2015
16th Sep 20157:00 amRNSImmunoBody presented at Cancer Vaccines Conference
27th Aug 20154:42 pmRNSNotice of AGM
30th Jul 20157:00 amRNSCollaboration with ImmunID
9th Jul 20157:00 amRNSPatient recruitment completed for SCIB1 trial
2nd Jun 20157:00 amRNSSCIB1 data update in resected melanoma patients
17th Apr 20159:00 amRNSPoster on Moditope to be presented at AACR
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
24th Mar 20157:00 amRNSSCIB2 synergy with checkpoint inhibitor blockade
12th Jan 20157:00 amRNSPositive SCIB1 Phase 1/2 clinical trial update
15th Dec 20145:22 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSHalf Yearly Report
22nd Oct 20143:07 pmRNSChange of Registered Office
14th Oct 20146:19 pmRNSResult of AGM
14th Oct 20147:00 amRNSAppointment of Nominated Adviser and Broker
14th Oct 20147:00 amRNSAGM research and development update
30th Sep 20147:00 amRNSPresent at the 14th Annual Biotech in Europe Forum
19th Sep 20149:57 amRNSNotice of AGM
12th Sep 20147:00 amRNSPresenting at Upcoming Scientific Conferences
4th Sep 20147:00 amRNSFinal Results
12th Aug 20147:00 amRNSSynergy of SCIB1 with checkpoint inhibitors
19th Jun 20147:00 amRNSDirector/PDMR Shareholding
6th Jun 20147:00 amRNSDNA ImmunoBody Patent Granted in United States
2nd Jun 20147:00 amRNSUpdate on Phase 1/2 trial of SCIB1 in melanoma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.